Search results
Showing 451 to 465 of 744 results for impact reports
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.
This guideline covers the planning and delivery of person-centred care for older people living in their own homes (known as home care or domiciliary care). It aims to promote older people's independence and to ensure safe and consistently high quality home care services.
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.